Therapeutic control of complement activation at the level of the central component C3

Immunobiology

Volumn 221, Issue 6, 2016, Pages 740-746

  Ricklin, Daniel ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alternative pathway; C3; Complement; Convertase; Therapeutics

Indexed keywords

AMY 101; BCX 1470; CB 2782; CDX 1135; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COBROTOXIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR D; COMPLEMENT FACTOR D INHIBITOR; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT INHIBITOR; COMPSTATIN DERIVATIVE; ECULIZUMAB; LAMPALIZUMAB; MONOCLONAL ANTIBODY; POT 4; PROPERDIN; TA 106; TT 30; UNCLASSIFIED DRUG;

AGE RELATED MACULAR DEGENERATION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DELAYED GRAFT FUNCTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TARGETING; GLOMERULOPATHY; GRAFT REJECTION; HUMAN; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; INNATE IMMUNITY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; MOLECULAR TARGETED THERAPY;

EID: 84973254952     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.06.012     Document Type: Review

References (66)

1. Alper C.A., Rosen F.S. Studies of the in vivo behavior of human C'3 in normal subjects and patients. J. Clin. Invest. 1967, 46:2021.
2. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., Tsokos G.C., Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J. Clin. Invest. 2005, 115:2444.
3. Bajic G., Yatime L., Klos A., Andersen G.R. Human C3a and C3a desArg anaphylatoxins have conserved structures, in contrast to C5a and C5a desArg. Protein Sci. 2012, 22:204.
4. Baudino L., Sardini A., Ruseva M.M., Fossati-Jimack L., Cook H.T., Scott D., Simpson E., Botto M. C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:1503.
5. Berends E.T., Mohan S., Miellet W.R., Ruyken M., Rooijakkers S.H. Contribution of the complement membrane attack complex to the bactericidal activity of human serum. Mol. Immunol. 2015, 65:328.
6. Botto M., Kirschfink M., Macor P., Pickering M.C., Wurzner R., Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774.
7. Craik C.S., Page M.J., Madison E.L. Proteases as therapeutics. Biochem. J. 2011, 435:1.
8. DiLillo D.J., Pawluczkowycz A.W., Peng W., Kennedy A.D., Beum P.V., Lindorfer M.A., Taylor R.P. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol. Immunol. 2006, 43:1010.
9. Ekdahl K.N., Lambris J.D., Elwing H., Ricklin D., Nilsson P.H., Teramura Y., Nicholls I.A., Nilsson B. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv. Drug Deliv. Rev. 2011, 63:1042.
10. Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816.
11. Fridkis-Hareli M., Storek M., Mazsaroff I., Risitano A.M., Lundberg A.S., Horvath C.J., Holers V.M. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705.
12. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol. Immunol. 2014, 61:110.
13. Harboe M., Garred P., Karlstrom E., Lindstad J.K., Stahl G.L., Mollnes T.E. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol. 2009, 47:373.
14. Harboe M., Ulvund G., Vien L., Fung M., Mollnes T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138:439.
15. Hillmen P., Muus P., Roth A., Elebute M.O., Risitano A.M., Schrezenmeier H., Szer J., Browne P., Maciejewski J.P., Schubert J., Urbano-Ispizua A., de Castro C., Socie G., Brodsky R.A. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 2013, 162:62.
16. Holers V.M., Rohrer B., Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 2013, 735:137.
17. Holz F.G., Li Z.R., Beres T., Le K., Strauss E. The MAHALO phase II study: safety, tolerability and evidence of activity of FCFD4514S (Anti-factor D) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Ophthalmologica 2013, 230:12.
18. Huang Y., Reis E.S., Knerr P.J., van der Donk W.A., Ricklin D., Lambris J.D. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. Chemmedchem 2014, 9:2223.
19. Janssen B.J., Christodoulidou A., McCarthy A., Lambris J.D., Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature 2006, 444:213.
20. Janssen B.J., Halff E.F., Lambris J.D., Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J. Biol. Chem. 2007, 282:29241.
21. Janssen B.J., Huizinga E.G., Raaijmakers H.C., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505.
22. Katschke, Stawicki K.J., Yin S., Steffek J., Xi M., Sturgeon H., Hass L., Loyet P.E., Deforge K.M., Wu L., van Lookeren Campagne Y., Wiesmann M., C Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J. Biol. Chem. 2009, 284:10473.
23. Katschke, Wu K.J., Ganesan P., Kelley R., Mathieu R.F., Hass M.A., Murray P.E., Kirchhofer J., Wiesmann D., van Lookeren Campagne C., M Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 2012, 287:12886.
24. Kimura Y., Zhou L., Miwa T., Song W.C. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury. J. Clin. Invest. 2010, 120:3545.
25. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115.
26. Lay E., Nutland S., Smith J.E., Hiles I., Smith R.A., Seilly D.J., Buchberger A., Schwaeble W., Lachmann P.J. Complotype affects the extent of down-regulation by factor I of the C3b feedback cycle in-vitro. Clin. Exp. Immunol. 2014, in press. 10.1111/cei.12437.
27. Lazar H.L., Kean T., Fzgerald C.A., Shapa O.M., Hunter C.T., Shem R.J., Marsh, HC, Ryan U.S., Group T.P.C.S.S. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?. Circulation 2007, 116. I83.
28. Lesher A.M., Nilsson B., Song W.C. Properdin in complement activation and tissue injury. Mol. Immunol. 2013, 56:191.
29. Lesher A.M., Zhou L., Kimura Y., Sato S., Gullipalli D., Herbert A.P., Barlow P.N., Eberhardt H.U., Skerka C., Zipfel P.F., Hamano T., Miwa T., Tung K.S., Song W.C. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J. Am. Soc. Nephrol. 2012, 24:53.
30. Li J.S., Jaggers J., Anderson P.A. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev. Cardiovasc. Ther. 2006, 4:649.
31. Loyet K.M., Good J., Davancaze T., Sturgeon L., Wang X., Yang J., Le K.N., Wong M., Hass P.E., Campagne M., Haughney P.C., Morimoto A., Damico-Beyer L.A., DeForge L.E. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J. Pharmacol. Exp. Ther. 2014, 351:527.
32. Maekawa T., Abe T., Hajishengallis E., Hosur K.B., DeAngelis R.A., Ricklin D., Lambris J.D., Hajishengallis G. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J. Immunol. 2014, 192:6020.
33. Mastellos D.C., Ricklin D., Yancopoulou D., Risitano A., Lambris J.D. Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Rev. Hematol. 2014, 7:583.
34. Mastellos D.C., Yancopoulou D., Kokkinos P., Huber-Lang M., Hajishengallis G., Biglarnia A.R., Lupu F., Nilsson B., Risitano A.M., Ricklin D., Lambris J.D. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Invest. 2015, 45:423.
35. Medical Research Council A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL). In: UK Clinical Research Network Study Portfolio [Internet; cited 2015 Feb 17]. Available from: UKCRNI dentifier: 16.181. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=16181.
36. Milder F.J., Gomes L., Schouten A., Janssen B.J., Huizinga E.G., Romijn R.A., Hemrika W., Roos A., Daha M.R., Gros P. Factor B structure provides insights into activation of the central protease of the complement system. Nat. Struct. Mol. Biol. 2007, 14:224.
37. Miwa T., Sato S., Gullipalli D., Nangaku M., Song W.C. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice. J. Immunol. 2013, 190:3552.
38. Morgan, B.P., Thanassi, J., Podos, S., Yang, G., Phadke, A., Gadhachanda, V., Pais, G., Hashimoto, A., Wang, Q., Chen, D., Wang, X., Agarwal, A., Deshpande, M., Huang, Y., Wiles, J., Huang, M. 2014. Novel small-molecule inhibitors targeting complement factor D for therapy of paroxysmal nocturnal hemoglobinuria, 56th ASH Annual Meeting and Exposition, San Francisco, CA.
39. Nagar B., Jones R.G., Diefenbach R.J., Isenman D.E., Rini J.M. X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. Science 1998, 280:1277.
40. Nilsson P.H., Ekdahl K.N., Magnusson P.U., Qu H., Iwata H., Ricklin D., Hong J., Lambris J.D., Nilsson B., Teramura Y. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials 2013, 34:985.
41. Paixao-Cavalcante D., Torreira E., Lindorfer M.A., Rodriguez de Cordoba S., Morgan B.P., Taylor R.P., Llorca O., Harris C.L. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. J. Immunol. 2014, 192:4844.
42. Pauly D., Nagel B.M., Reinders J., Killian T., Wulf M., Ackermann S., Ehrenstein B., Zipfel P.F., Skerka C., Weber B.H. A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples. PLoS One 2014, 9:e96371.
43. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013, 218:496.
44. Reis E.S., DeAngelis R.A., Chen H., Resuello R.R., Ricklin D., Lambris J.D. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 2014, 220:476.
45. Reis E.S., Falcao D.A., Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 2006, 63:155.
46. Ricklin D. Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology 2012, 217:1057.
47. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785.
48. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273.
49. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 2013, 190:3831.
50. Ricklin D., Lambris J.D. Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 2013, 190:3839.
51. Ricklin D., Lambris J.D. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 2013, 735:1.
52. Risitano A.M., Notaro R., Pascariello C., Sica M., del Vecchio L., Horvath C.J., Fridkis-Hareli M., Selleri C., Lindorfer M.A., Taylor R.P., Luzzatto L., Holers V.M. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012, 119:6307.
53. Risitano A.M., Ricklin D., Huang Y., Reis E.S., Chen H., Ricci P., Lin Z., Pascariello C., Raia M., Sica M., Del Vecchio L., Pane F., Lupu F., Notaro R., Resuello R.R., DeAngelis R.A., Lambris J.D. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014, 123:2094.
54. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009, 10:721.
55. Roversi P., Johnson S., Caesar J.J., McLean F., Leath K.J., Tsiftsoglou S.A., Morgan B.P., Harris C.L., Sim R.B., Lea S.M. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12839.
56. Ruseva M.M., Vernon K.A., Lesher A.M., Schwaeble W.J., Ali Y.M., Botto M., Cook T., Song W., Stover C.M., Pickering M.C. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J. Am. Soc. Nephrol. 2013, 24:43.
57. Sacks S., Karegli J., Farrar C.A., Asgari E., Schwaeble W., Zhou W., Smith R.A. Targeting complement at the time of transplantation. Adv. Exp. Med. Biol. 2013, 735:247.
58. Sacks S.H., Zhou W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 2012, 12:431.
59. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 1996, 157:884.
60. Schmidt C.Q., Bai H., Lin Z., Risitano A.M., Barlow P.N., Ricklin D., Lambris J.D. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 2013, 190:5712.
61. Scott D., Botto M. The paradoxical roles of C1q and C3 in autoimmunity. Immunobiology 2016, 221:719.
62. Vogel C.W., Finnegan P.W., Fritzinger D.C. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Mol. Immunol. 2014, 61:191.
63. Wiles, J., Podos, S., Thanassi, J., Phadke, A., Gadhachanda, V., Pais, G., Hashimoto, A., Wang, Q., Chen, D., Wang, X., Agarwal, A., Rivera, J., Elliot, M., Marlor, C., Zhang, J., Fabrycki, J., Patel, D., Deshpande, M., Huang, M., Huang, Y. 2014. Preclinical evaluation of orally bioavailable small-molecule inhibitors of complement factor D as a potential treatment for paroxysmal nocturnal hemoglobinuria, 56th ASH Annual Meeting and Exposition, San Francisco, CA.
64. Wu J., Wu Y.Q., Ricklin D., Janssen B.J., Lambris J.D., Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 2009, 10:728.
65. Wu Y.Q., Qu H., Sfyroera G., Tzekou A., Kay B.K., Nilsson B., Nilsson Ekdahl K., Ricklin D., Lambris J.D. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 2011, 186:4269.
66. Zhang Y., Shao D., Ricklin D., Hilkin B.M., Nester C.M., Lambris J.D., Smith R.J. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 2015, 220:993.